how to qualify for glp-1 Indications GLP-1/GIP RA Summary Sheet and Beyond! Navigating Insurance for GLP-1 Medication:

[DOI] [PubMed] [Google Scholar] 159.Snchez-Garrido M.A., Brandt S.J., Clemmensen C., Mller T.D., DiMarchi R.D., Tschp M.H

Obesity also increases the risk of cardiovascular disease, where 5 kg increases in weight in adults is associated with an 11% higher risk of death from cardiovascular disease (strokes, coronary heart disease, myocardial infarction etc)

Given the relatively high monthly cost of GLP-1s in the US, as well as the prevalence of obesity in that market, GLP-1s have attracted particular attention

Most people lose, on average, 3-8% of their muscle mass every ten years after age 30

That finding surprised many researchers and requires careful interpretation

In SELECT, a trial of more than 17,000 people on semaglutide, serious adverse events were actually lower than on placebo, about 33 percent versus 36 percent (Lincoff et al., 2023)